Achieved preliminary record total quarterly revenue of $9.8 million and product sales of $9.5 million, driven by demand for CytoSorb as a treatment of cytokine storm in COVID-19 infection and other illnesses. MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat […]
Author: Ken Dropiewski
Spectral MD and the American College of Cardiology to Advance Care for Critical Limb Ischemia
Spectral MD and the ACC will collaborate to provide scientific oversight and assessment of the clinical value of Spectral MD’s DeepView technology to detect and assess critical limb ischemia DALLAS, July 21, 2020 /PRNewswire/ — Spectral MD and the American College of Cardiology (ACC) announced today that they will collaborate to investigate the […]
ViralClear Announces Formation of Its Scientific Advisory Board
Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) — BioSig Subsidiary Enlists Seasoned Professionals in Emerging Infectious Diseases and Regulatory Development to Its Advisory Board ViralClear Pharmaceuticals is Currently in Phase II Trials with Its Lead Asset Merimepodib in the Fight Against COVID-19 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) […]
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), today announced the Company’s registration statement on Form S-1 relating to its equity credit line with Calvary Fund I LP has been ordered effective by the Securities and Exchange Commission. This equity […]
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious […]
XyloCor Therapeutics Doses Patients in Phase 1/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina
– Novel gene therapy designed to stimulate formation of new coronary blood vessels is being studied in patients with treatment-resistant angina with no remaining treatment options – July 21, 2020 07:00 AM Eastern Daylight Time MALVERN, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics today announced it has successfully dosed the first two patients in […]
Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the expansion of its Board of Directors with the appointment of Steven Boyd and Keith Maher, M.D. Both Directors […]
Paragonix Technologies Receives Coveted International Design Award for Novel Organ Transportation System
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced that its flagship product, Paragonix SherpaPak™ Cardiac Transport System (CTS), is the recipient of a prestigious international design award: the Red Dot Award. The traditional mechanism by which organs are transported (bagged on ice in a consumer cooler) has remained unchanged for more than […]
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study There are approximately 175,000 and 150,000 ESKD patients with PAD […]
Shockwave Appoints Maria Sainz to Board of Directors
SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwave’s Compensation Committee. “I am delighted […]



